Disc Medicine, Inc. Common Stock IRON
Analyst Ratings
- Consensus
- Buy — 8 Buy · 0 Hold · 0 Sell (8 analysts)
- Avg. Price Target
- $120.13 (+50.5% upside)
Key Stats
- Today's Range
- $74.52 – $80.00
- 50-Day Range
- $55.00 – $83.63
- 52-Week Range
- $40.00 – $99.50
- Volume
- 1.24 million shs
- Average Volume
- 919K shs
- Market Cap
- $3.03 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.76%
- Days to Cover
- 5.83
About Disc Medicine, Inc. Common Stock
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Related Stocks
Compare head-to-head: IRON vs LLY·IRON vs JNJ·IRON vs ABBV·IRON vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.